CDKN2A and astrocytoma (excluding glioblastoma): Cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion in IDH1/2 mutant astrocytoma associates with a poor prognosis, similar to WHO IV tumors (9).